Mutation Status of K-ras, p53 and Allelic Losses at 9p and 18q Are Not Prognostic Markers in Patients with Pancreatic Cancer

Abstract

K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 are perceived as potential markers for screening of pancreatic malignancy. In this study, molecular data is compared with survival statistics of the patients and whether they correlate with patients' prognosis is questioned.

Keywords

• pancreatic cancer
• k-ras
• p53
• p16
• DPC4
• prognostic markers
• ductal adenocarcinoma
• clinicopathological parameters
• epigenetic alterations
• clinical-relevance
• tumor-marker
• expression
• carcinoma
• diagnosis
• survival
• chemotherapy